Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2008

View Archived Issues

Pim-2 kinase inhibitors identified as potential drugs for the treatment of inflammation

CB2 ligands developed at Abbott undergoing optimization

Urotensin-II receptor antagonist optimization leads to JNJ-39327041

Characterization of Pfizer's novel CP-690550 in de novo kidney transplant patients

Novel antiviral agents claimed by Novartis

Oncothyreon presents update on clinical development activities

Chelsea Therapeutics initiates patient dosing in Study 301 phase III trial of droxidopa in NOH

Neurocrine presents elagolix PETAL study results in endometriosis

FDA approves Sandoz's Omnitrope Pen 10 with liquid cartridge for growth hormone deficiency

PHA-848125, a novel CDK inhibitor orally active in preclinical model of ovarian carcinoma

Ikaria acquires North American rights to Lucassin for HRS from Orphan Therapeutics

Refinement of H3 receptor antagonists for wakefulness continues at Arena Pharmaceuticals

Wyeth advances synthesis of dual selective serotonin reuptake inhibitors/5-HT1A antagonists

Diffusion initiates phase I/II trans-sodium crocetinate trial in patients with PAD

Recent patents cover novel anticancer agents

OSI initiates clinical development program for antidiabetes candidate, PSN-821

Plexxikon commences phase I trial for novel kinase inhibitor, PLX-5568

New immunmodulatory agents disclosed by Otsuka Chemical

Sangamo BioSciences initiates phase II trial for SB-509 in ALS

Agile achieves phase II study endpoints with low-dose contraceptive patch

Phase II study shows Arcalyst reduces gout flares by 81%

OncoGenex grants Eagle Pharmaceuticals exclusive worldwide rights to Tocosol paclitaxel

Anavex successfully completes preclinical studies of ANAVEX 2-73 in Alzheimer's disease

Dako acquires InstrumeC

ZymoGenetics and Merck Serono restructure 2001 partnership agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...